Chronic myelomonocytic leukemia “myelodysplastic type’’ in transformation to acute myeloid leukemia – diagnostic and therapeutic options: case report and literature review / Leucemie mielomonocitară cronică forma mielodisplazică în transformare spre leucemie acută mieloidă – diagnostic și opțiuni terapeutice: prezentare de caz și revizuirea literaturii

Open access


Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder that is characterized by the presence of an absolute monocytosis (1 × 10^ 9/l) in the peripheral blood, the overlap of myelodisplastic aspects and myeloproliferative aspects in the bone marrow and tendency to transform into acute myeloid leukemia. CMML is considered to be the most aggressive chronic myeloid leukemia. We present the case of a 48 years old woman who was hospitalized in March 2013 in the Center of Hematology and Bone Marrow Transplantation for anemia related symptoms. Initial investigations showed anemia, relative monocytosis (10% monocytes of the WBC differential) with an increasing absolute number of monocytes (> 1,000/μl) in the following months. Initial exploration of the bone marrow (aspirate and bone marrow biopsy and immunohistochemistry IHC tests) revealed elements of trilinear dysplasia and an increased percentage of myeloblasts (11-14%). In the next four months myeloblasts percentage remained below 20% (8-14%) and it has been observed a gradually increasing of monocytoid elements (> 20%). Immunophenotyping in the bone marrow aspirate identified a monocytic proliferation with high percentage (8%) of immature cells. The karyotype reported the presence of clones with t (1;3). Initially diagnosed as RAEB-2 (WHO) the case was recomitted in CMML-type 2 with a progression to acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been performed after getting the best possible therapeutic response with AML chemotherapy type (complete remission). Allo-HSCT was performed using myeloablative conditioning, 12 months after diagnosis. The patient is now in complete remission, 24 months after allo-HSCT.

1. Orazi A, Bennett JM, Germing U, Brunning RD, Bain BJ, Thicle J. Chronic myelomonocytic leukaemia, Swerdlow S, Campos E, Lee Harris NL, Jaffe ES, Stefano PA, Stein H, et al, editors. WHO Classification of tumours of haematopoietic and lymphoid tissues: Lyon, France: International Agency for Research on Cancer. 2008:74-79.

2. Vardiman JW, Thile J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul;114(5):937-51.DOI: 10.1182/blood-2009-03-209262.

3. Bennett JM, Catovsky O, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 June;51(2):189-99. DOI: 10.1111/ j.1365-2141.1982.tb08475.x.

4. Arber DA, Orazi A, Hasserjan R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May;127(20):2391-2405. DOI: 10.1182/blood-2016-03-643544.

5. Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E, et al. Cytogenetic stratification in chronic myelomonocytic leukemia. Haematologica. 2011 Mar;96(3):375-383. DOI: 10.3324/haematol.2010.030957

6. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, et al. Clonal architecture of chronic myelomonocytic leukemia. Blood. 2013 Mar;121(12):2186-98. DOI: 10.1182/ blood-2012-06-440347.

7. Mughal TI, Cross NCP, Padron E, Tiu RV, Savona M, Malcovati L. An International MDS/ MPN Working Group’s Perspective and Recommendations on Molecular Pathogenesis, Diagnosis and Clinical Characterization of Myelodysplastic/ myeloproliferative Neoplasm. Haematologica. 2015 Sep;100(9):1117-30. DOI: 10.3324/haematol.2014.114660.

8. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008 Jul;112(1):45-52. DOI: 10.1182/blood-2008-01-134858.

9. Gologan R, Berceanu A, Colita A, Codreanu V, Dobrea C, Geoada L, et al. Clinical and Hematological Aspects of Chronic Myelomonocytic Leukemia. Study on 20 cases from a single center from Romania. Rom J Intern Med. 2002;40(1-4):95-102.

10. Patiu M, Plesa A, Cucuianu A. Chronic myelomonocytic leukemia. A comparative study of the subtype: dysplasia and proliferative. Documenta Haematologica. 2000;5:63-68.

11. Colita A, Colita D, Gologan R. A single Center retrospective analysis of 42 cases of chronic myelomonocytic leukemia – poster presentation: Paris, France: The 7th International Meeting on MDS.2003.

12. Wang Sa A, Galili N, Cerny J, Sechman E, Chen SS, Loew J, et al. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. An J. Clin. Pathol. 2006 Nov;126(5):789-97. DOI: 10.1309/ FU04P779U310R3EE.

13. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO – defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Jul;27(7):1504-10. DOI: 10.1038/leu.2013.88.

14. Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B, et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica. 2007 Jul;92:974-7. DOI: 10.3324/haematol. 11051.

15. Schuler E, Schroeder M, Neukirchen J, Strupp C, Xicoy B, Kundgen A, et al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leukemia Research. 2014 Sep;38:1413-19. DOI: 10.1016/j.leukres.2014.09.003.

16. Onida F, Baroni G, Leone G, Malcovati L, Morra E, Santini V, et al. Management recommendations for chronic myelomonocytic leukemia: conseum statements from the SIE, SIES, GITMO groups. Haematologica. 2013 Sep;98(9):1344-52. DOI: 10.3324/haematol.2013.084020.

17. Such E, Germing U, Malcovati L, Cervera J, Kuengen A, Porta MGD, et al. Development and validation of a prognostic scoring system for patients. Blood. 2013 Apr;121(15):3005-15. DOI: 10.1182/ blood-2012-08-452938.

18. Calvo X, Nomdedeu M, Santacruz R, Martinez N, Costa D, Pereira A, et al. Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML- specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. Leukemia Research. 2015 Jul;39:1146-53. DOI: 10.1016/j.leukres.2015.05.017.

19. Shaffer LG, McGowan-Jordan J, Schmid M. ISCN 2013: An International System for Human Cytogenetic Nomenclature (2013): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland: 2013: 78-79.

20. Kekre N, Ho VT. Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia. Am J Hematol. 2015 Nov;91(1):123-30. DOI: 10.1002/ajh.24215.

21. Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the chronic malignancies working party of the European group for blood and marrow transplantation. Br J Haematol. 2015 Jul;171(2):239-46. DOI: 10.1111/bjh.13576.

22. Duong Hk, Akhtari M, Ahn KW, Hu ZH, Popat UR, Alyea III EP, et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Bio Blood Marrow Transplant. 2015 Feb;21(2):S30-S31. DOI: 10.1016/j.bbmt.2014.11.022.

23. Kongtim P, Popat U, Jimenez A, Gaballa S, Fakih RE, Rondon G, et al. Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression free survival for patients with chronic myelomonocytic leukemia. Bio Blood Marrow Transplant. 2016 Jan;22(1):47-53. DOI: 10.1016/j.bbmt.2015.08.031.

24. Sharma P, Shinde S, Patnaik M. Outcomes of allogeneic stem cell transplant in patients with chronic myelomonocytic leukemia (CMML) – A single institution experience. Biol Blood Marrow Transplant. 2015 Feb; 21(2):S193-S194. DOI: 10.1016/j.bbmt.2014.11.293.

25. Park S, Labopin M, Agha IY, Delaunay J, Dhedin N, Deconinck E, et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: A report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol. 2013 May;90(5):355-64. DOI: 10.1111/ejh.12073.

26. Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K et al – Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: Relapse- free survival is determined by karyotype and comorbidities. Bio Blood Marrow Transplant. 2011 Jun;17(6):908-15. DOI: 10.1016/j.bbmt.2010.09.018.

27. Krishnamurthy P, Lim Zy, Nagi W, Kenyon M, Mijovic A, Ireland R -Allogeneic haematopoietic SCT for chronic myelomonocytic leukemia: A single- centre experience. Bone Marrow Transplant. 2010 Jan;45:1502-7. DOI: 10.1038/bmt.2009.375.

28. Ocheni S, Kroger N, Zabelina T, Zander AR, Bacher U. Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2009 Apr;43(8):659-61. DOI: 10.1038/bmt.2008.366.

29. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006 Jun;37(11):1003-8. DOI: 10.1038/sj.bmt.1705369.

30. Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005 Sep;11(9):713-20. DOI: 10.1016/j.bbmt.2005.05.008

31. Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukemia: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Tranplantation (EBMT). Br. J Haematol. 2002 Jul;118(1):67-73. DOI: 10.1046/j.1365-2141.2002.03552.x.

32. Cheng H, Kirtani VG, Gergis U. Current status of allogeneic HST for chronic myelomonocytic leukemia. Bone Marrow Transplantation. 2012 Apr;47(4):535-41. DOI: 10.1038/bmt.2011.141.

33. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophsysiological review. Br J Haematol. 2014 May;165(3):273-86. DOI: 10.1111/bjh.12756.

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information

IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 261 175 11
PDF Downloads 87 73 4